Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

•Aficamten is a next-generation cardiac myosin inhibitor (CMI)•CMIs are a novel treatment for obstructive hypertrophic cardiomyopathy (oHCM)•We report efficacy and safety of aficamten with disopyramide for refractory oHCM•In Cohort 3 of REDWOOD-HCM, aficamten plus disopyramide was well tolerated•Pat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiac failure 2023-11, Vol.29 (11), p.1576-1582
Main Authors: Owens, Anjali T., Masri, Ahmad, Abraham, Theodore P., Choudhury, Lubna, Rader, Florian, Symanski, John D., Turer, Aslan T., Wong, Timothy C., Tower-Rader, Albree, Coats, Caroline J., Fifer, Michael A., Olivotto, Iacopo, Solomon, Scott D., Watkins, Hugh C., Heitner, Stephen B., Jacoby, Daniel L., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Sohn, Regina, Wohltman, Amy, Maron, Martin S.
Format: Article
Language:English
Subjects:
Aficamten
Anti-Arrhythmia Agents
Cardiomyopathy, Hypertrophic - drug therapy
Disopyramide - adverse effects
Heart Failure - drug therapy
Humans
obstructive hypertrophic cardiomyopathy
REDWOOD-HCM
refractory obstructive hypertrophic cardiomyopathy
Sequoia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Aficamten is a next-generation cardiac myosin inhibitor (CMI)•CMIs are a novel treatment for obstructive hypertrophic cardiomyopathy (oHCM)•We report efficacy and safety of aficamten with disopyramide for refractory oHCM•In Cohort 3 of REDWOOD-HCM, aficamten plus disopyramide was well tolerated•Patients had improved left ventricular outflow tract gradient and NYHA class
ISSN:1071-9164
1532-8414
1532-8414
DOI:10.1016/j.cardfail.2023.07.003